GoAI
Get started
Nutriband Inc. logo

Nutriband Inc.

NTRB

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.6664

+$0.8514 · +22.32%

Aug 21, 4:00 PM ET

Pre-market

$4.78

+$0.1136 · +2.43%

Aug 24, 5:43 AM ET

NTRB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

28

Expensive

Momentum

18

Strong Down

Sentiment

52

Mixed

Risk resilience

18

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Gareth Sheridan
Listed since
Oct 1, 2021
Employees
13

Market position

Day range

Current $4.6664

52-week range

Current $4.6664

Open
$3.88
Previous close
$3.815
Volume
65.6K
5.86× average
Average volume
11.19K
Average daily volume
Market cap
56.72M USD
Beta
1.97
Market reference 1
50-day average
$3.1375
+48.73% above average
200-day average
$4.0077
+16.43% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
51.43M USD
P/E (TTM)
-1.78×
P/B (TTM)
9.47×
P/S (TTM)
31.47×
EV / EBITDA
-6.42×
Earnings yield
-14.76%
Free cash flow yield
-9.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
28.35%
Operating margin
-452.61%
Net margin
-448.39%
Return on equity
-123.21%
Return on assets
-109.03%
Return on invested capital
-120.12%

Financial health

Debt / equity
0.04×
Current ratio
6.36×
Altman Z-score
25
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends105%-149%-402%-656%Gross margin, FY2021: 35.46%Gross margin, FY2022: 36.08%Gross margin, FY2023: 41.34%Gross margin, FY2024: 32.68%Gross margin, FY2025: 27.81%Operating margin, FY2021: -276.33%Operating margin, FY2022: -199.45%Operating margin, FY2023: -233.63%Operating margin, FY2024: -312.62%Operating margin, FY2025: -408.41%Net margin, FY2021: -592.23%Net margin, FY2022: -231.33%Net margin, FY2023: -263.04%Net margin, FY2024: -489.86%Net margin, FY2025: -404.08%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 35.46%. Gross margin FY2022 36.08%. Gross margin FY2023 41.34%. Gross margin FY2024 32.68%. Gross margin FY2025 27.81%. Operating margin FY2021 -276.33%. Operating margin FY2022 -199.45%. Operating margin FY2023 -233.63%. Operating margin FY2024 -312.62%. Operating margin FY2025 -408.41%. Net margin FY2021 -592.23%. Net margin FY2022 -231.33%. Net margin FY2023 -263.04%. Net margin FY2024 -489.86%. Net margin FY2025 -404.08%.

Income trends

Revenue

2.04M USD-4.83%

Operating income

−8.32M USD-24.33%

Net income

−8.23M USD+21.50%
Income trends across reported periods3.4M USD−1.65M USD−6.7M USD−11.75M USDRevenue, FY2021: 1.42M USDRevenue, FY2022: 2.08M USDRevenue, FY2023: 2.09M USDRevenue, FY2024: 2.14M USDRevenue, FY2025: 2.04M USDOperating income, FY2021: −3.93M USDOperating income, FY2022: −4.15M USDOperating income, FY2023: −4.87M USDOperating income, FY2024: −6.69M USDOperating income, FY2025: −8.32M USDNet income, FY2021: −8.42M USDNet income, FY2022: −4.81M USDNet income, FY2023: −5.49M USDNet income, FY2024: −10.48M USDNet income, FY2025: −8.23M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.42M USD. Revenue FY2022 2.08M USD. Revenue FY2023 2.09M USD. Revenue FY2024 2.14M USD. Revenue FY2025 2.04M USD. Operating income FY2021 −3.93M USD. Operating income FY2022 −4.15M USD. Operating income FY2023 −4.87M USD. Operating income FY2024 −6.69M USD. Operating income FY2025 −8.32M USD. Net income FY2021 −8.42M USD. Net income FY2022 −4.81M USD. Net income FY2023 −5.49M USD. Net income FY2024 −10.48M USD. Net income FY2025 −8.23M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.04M USD2.14M USD2.09M USD2.08M USD1.42M USD
Cost of goods sold1.47M USD1.44M USD1.22M USD1.33M USD917.84K USD
Gross profit566.31K USD699.3K USD862.11K USD750.41K USD504.31K USD
Research and development1.89M USD3.12M USD1.96M USD982.23K USD411.38K USD
Selling, general, and administrative6.99M USD4.27M USD3.77M USD3.92M USD4.02M USD
Operating expenses8.88M USD7.39M USD5.73M USD4.9M USD4.43M USD
Interest income—191.67K USD16.85K USD——
Interest expense22.54K USD21.41K USD75.82K USD8.29K USD118.42K USD
Depreciation and amortization193.8K USD285.05K USD287.72K USD368.96K USD318.26K USD
Operating income−8.32M USD−6.69M USD−4.87M USD−4.15M USD−3.93M USD
Net income−8.23M USD−10.48M USD−5.49M USD−4.81M USD−8.42M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
30%
3 beats, 6 misses, 1 met estimate
Average EPS surprise
-181.57%
10 comparable reports
Latest EPS result
-0.1

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.79-1.54-2.3Q3 '24MissQ4 '24MetQ2 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ2 '26BeatQ2 '26No estimate
Q3 2024, reported Sep 3, 2024: actual -0.12, estimate -0.05, surprise -140.00%, Miss. Q4 2024, reported Dec 3, 2024: actual -0.12, estimate -0.12, surprise 0.00%, Met estimate. Q2 2025, reported Apr 28, 2025: actual -0.5, estimate -0.12, surprise -316.67%, Miss. Q2 2025, reported May 30, 2025: actual -0.12, estimate -0.13, surprise +7.69%, Beat. Q3 2025, reported Sep 9, 2025: actual -2.12, estimate -0.17, surprise -1147.06%, Miss. Q4 2025, reported Dec 16, 2025: actual -0.12, estimate -2.13, surprise +94.37%, Beat. Q2 2026, reported Apr 29, 2026: actual -0.04, estimate -1.89, surprise +97.88%, Beat. Q2 2026, reported Jun 11, 2026: actual -0.1, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates798.52K636.52K474.53K312.54KQ3 '24MissQ4 '24MissQ2 '25MetQ2 '25MetQ3 '25MetQ4 '25MissQ2 '26MissQ2 '26No estimate
Q3 2024, reported Sep 3, 2024: actual 442.83K USD, estimate 675K USD, surprise -34.40%, Miss. Q4 2024, reported Dec 3, 2024: actual 646K USD, estimate 710K USD, surprise -9.01%, Miss. Q2 2025, reported Apr 28, 2025: actual 642K USD, estimate 642K USD, surprise 0.00%, Met estimate. Q2 2025, reported May 30, 2025: actual 667K USD, estimate 667K USD, surprise 0.00%, Met estimate. Q3 2025, reported Sep 9, 2025: actual 622K USD, estimate 622K USD, surprise 0.00%, Met estimate. Q4 2025, reported Dec 16, 2025: actual 346.06K USD, estimate 675K USD, surprise -48.73%, Miss. Q2 2026, reported Apr 29, 2026: actual 400.71K USD, estimate 765K USD, surprise -47.62%, Miss. Q2 2026, reported Jun 11, 2026: actual 433.4K USD, estimate —, surprise —, Comparison unavailable.

NTRB news

Corporate actions

Corporate action history

Stock split

Effective Aug 12, 2022

583:500

Stock split

Effective Jul 24, 2019

1:4

NTRB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding NTRB

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
0.31
Weight
—
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
0.13
Weight
—
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
0.02
Weight
—
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research NTRB

research.disclaimer